仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Brentuximab vedotin （cAC10-vcMMAE） is an antibody-drug conjugate （ADC） comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E （MMAE）. Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma